Market Intelligence
The ProGen Radar
Fortnightly market intelligence on radiopharma, CDMO, ADC, and cell and gene therapy. Built from live executive search mandates and operator conversations.
ProGen Radar comes in two formats. Choose what fits.
Free
ProGen Radar
Fortnightly briefing on radiopharma, CDMO, ADC, and CGT. Available on LinkedIn or by email.
Subscribe free →ProGen Radar Pro
Long-form fortnightly memo. 3,500 to 4,500 words of deep analysis, deal flow, and forward calendar. Built from live executive search mandates.
See what's inside →Free Tier
Read it free on LinkedIn or by email
The free Radar is a short fortnightly briefing on what is actually moving across radiopharma, CDMO, ADC, and cell and gene therapy. Sector pulse, deal flow, talent shifts, and the operator-level signal behind the headlines.
Written by Byron Fitzgerald from live executive search mandates. No filler, no recycled press releases. Read by VPs and C-suite at biotechs, CDMOs, and investors across life sciences.
4,000+
Email subscribers across life sciences
33,000+
LinkedIn followers reading each issue
Newsletter
Get the ProGen Radar
Free, fortnightly, by email. Same signal that runs on LinkedIn.
No spam. Unsubscribe anytime.
Paid Tier
ProGen Radar Pro
The fortnightly long-form intelligence memo. Same modalities, much deeper analysis.
The free Radar tells you what moved. Pro tells you what it means.
3,500 to 4,500 words every fortnight, drawn from live executive search mandates and operator conversations. Sector deep-reads on Radiopharma, CGT, and ADCs. The hiring patterns that signal company strategy before press releases catch up. One long strategic piece each issue.
This is the memo I write when something needs proper analysis. The free Radar can only carry the headline. Pro carries the structure.
What is included with Pro
Every fortnight
~25 minute read. Delivered every other Friday.
The Setup - 200 word framing of what shifted this fortnight
Sector Pulse: Radiopharma - 300 to 400 words on what is moving in the sector
Sector Pulse: CGT - 300 to 400 words on cell and gene therapy
Sector Pulse: ADC - 300 to 400 words on antibody-drug conjugates
Deal Flow Watch - capital movements, M&A signal, partnership economics
The Deeper Read - one long strategic piece on a single thread (1,200+ words)
People Moves - 5 to 10 senior hires and exits worth knowing about
The Calendar - what is coming in the next fortnight
Subscriber benefits
Ongoing perks while your subscription is active.
20% off every paid intelligence report - the State of Radiopharmaceuticals, the State of ADCs, the Isotope Production Map, and every future flagship release. See the current report catalogue →
Meaningful value per purchase - the discount on a single-user license ($1,495) saves $299, three months of Pro at no additional cost. On an enterprise license ($5,995), it covers a full year of subscription.
Why I write this
I run retained executive search at VP to C-suite level across radiopharma, CDMO, ADC, and cell and gene therapy. That means I see the operator-level signal before it shows up in press releases. The hires that telegraph commercial strategy. The deal-flow patterns that precede consolidation. The capacity moves that change competitive dynamics.
Pro is where I write that down. Not desk research. Not sector commentary. Actual analysis from inside live mandates and operator rooms.
Byron Fitzgerald, Founder, ProGen Search
Who subscribes
Pro is built for operators and investors making capital and capacity decisions in complex life sciences.
- Site Heads, COOs, and VPs at CDMOs tracking competitor capacity moves
- Biotech CSOs and Heads of Strategy benchmarking partnership economics
- Life sciences investors building or pressure-testing conviction
- Board members preparing for quarterly reviews
- Business Development leaders watching competitor commercial moves
ProGen Radar Pro
Cancel anytime, no annual lock-in.
SubscribeDelivered fortnightly to your inbox. First issue within two weeks of subscribing.
Risk-free first issue
If your first Pro issue does not deliver on what is promised here, email me within 14 days. I will refund you in full. No forms, no questions.
What Pro is not
Pro is built to do one thing well. To keep the memo focused, the subscription does not include:
- Daily emails or breaking-news alerts
- A member portal or login system
- A private Slack or Discord community
- On-demand consulting or office hours
Just the memo. Every fortnight. Directly to your inbox.
What to Expect
Questions, answered
How is Pro different from the free Radar?
The free version is a shorter LinkedIn-style update on the most important shifts in the sector. Pro is a long-form analytical memo with deeper strategic reads, sector deal flow, and forward calendar intelligence.
What modalities does Pro cover?
Radiopharma, CGT, and ADCs in every issue. Heaviest on radiopharma, given current market activity.
Can I cancel?
Yes, anytime. No annual lock-in.
What if I do not get value from the first issue?
Email me within 14 days of subscribing and I will refund you in full. No forms, no questions.
Who reads it?
VPs and C-suite at biotechs, CDMOs, and investors across life sciences.